HIGHLIGHTS
- who: Androgen et al. from the Department of Biochemistry and Molecular Genetics, University of Virginia School of Medicine, Charlottesville, VA, USA have published the article: Induction of PARP7 Creates a Vulnerability for Growth Inhibition by RBN2397 in Prostate Cancer Cells, in the Journal: (JOURNAL) of 17/04/2023
- what: The authors show that the growth inhibitory effects of RBN2397 are distinct from its enhancement of interferon signaling recently shown to promote tumor immunogenicity. The authors explore RBN2397 as a PARP7 inhibitor in prostate cancer cells. In cells, the authors show that RBN2397 has nanomolar potency . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.